The research, recently published in JAMA Ophthalmology, found that patients taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—which include Ozempic, Wegovy, and Rybelsus—had more than twice the risk of developing neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, a leading cause of blindness in older adults. Does GLP-1 Plus from Advanced Bionutritionals share this liability, or perhaps other downsides of those pharmaceuticals working through GLP-1 as a mechanism? What is most important for us to know?

DWQA Questions › Category: Healing Modalities › The research, recently published in JAMA Ophthalmology, found that patients taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—which include Ozempic, Wegovy, and Rybelsus—had more than twice the risk of developing neovascular age-related macular degeneration (nAMD), also known as “wet” AMD, a leading cause of blindness in older adults. Does GLP-1 Plus from Advanced Bionutritionals share this liability, or perhaps other downsides of those pharmaceuticals working through GLP-1 as a mechanism? What is most important for us to know?

0 Vote Up Vote Down

Nicola Staff asked 4 hours ago

Fortunately, we do not see the same liability with the nutraceutical approach because there is a different way in which the GLP-1 receptor is addressed, and that is the key in avoiding the downside, with respect to vision, for some individuals over time taking a GLP-1 receptor agonist injection.